Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 145.00
Bid: 145.20
Ask: 147.00
Change: -1.40 (-0.96%)
Spread: 1.80 (1.24%)
Open: 146.00
High: 147.40
Low: 145.00
Prev. Close: 146.40
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

19 Jan 2023 07:00

RNS Number : 1883N
Elementis PLC
19 January 2023
 

Elementis plc

Trading Update

Full-year results in line with expectations; leverage reduction on track

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months and year ended 31 December 2022(1).

Business performance

 

The Group delivered a solid performance during the fourth quarter, despite experiencing weaker trading conditions as the macro-economic environment deteriorated through the period. Underlying operating profit for 2022 (including Discontinued Operations) is expected to be in the range $120-123m, in line with market expectations(2) and significantly ahead of the prior year.

 

· Coatings performed well, with pro-active pricing actions and product mix improvement offsetting weaker demand in European and Asian markets and customer destocking.

 

· Personal Care continued to perform strongly. In Cosmetics, pricing actions more than offset continuing cost inflation and some weakening of demand in certain regions. AP Actives demand remained robust.

 

· Talc performance remained materially below the prior year, due to continued volume weakness in its European markets, in particular automotive, and higher energy and logistics costs.

Balance Sheet

 

Net debt at the end of 2022 is anticipated to be approximately $367m (excluding lease liabilities), representing a leverage ratio of 2.2x net debt to EBITDA(3), down from 2.6x at the start of the year.

The sale of the Chromium business remains on track to complete during the first quarter of 2023 and to deliver net cash proceeds of approximately $107m, further reducing the Group's leverage ratio.

 

Preliminary full-year 2022 Results will be released on 7 March 2023.

 

 

Enquiries :

Elementis plc

David Boyd, Investor Relations Tel: +44 7764 905135

 

Tulchan

Martin Robinson Tel: 020 7353 4200

Olivia Peters

 

 

(1) Including the Chromium business which will be reported in 2022 as "Asset Held for Sale" and "Discontinued Operation".

(2) Based on company compiled consensus, the Board believes the average market forecast for 2022 adjusted operating profit (including Discontinued Operations) to be $121m.

(3) Excluding IFRS 16 impact

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTMZGMMRRRGFZM
Date   Source Headline
1st Apr 20208:13 amRNSDirector Declaration
25th Mar 20204:04 pmRNSAnnual Financial Report
25th Mar 202010:19 amRNSHolding(s) in Company
24th Mar 20209:02 amRNSHolding(s) in Company
23rd Mar 20205:25 pmRNSHolding(s) in Company
20th Mar 20205:28 pmPRNDirector/PDMR Shareholding
20th Mar 20205:07 pmRNSDirector/PDMR Shareholding
20th Mar 20205:06 pmRNSDirector/PDMR Shareholding
20th Mar 202010:44 amRNSHolding(s) in Company
19th Mar 20204:28 pmRNSDirector/PDMR Shareholding
19th Mar 20204:25 pmRNSDirector/PDMR Shareholding
19th Mar 20204:24 pmRNSDirector/PDMR Shareholding
19th Mar 20207:00 amPRNCOVID-19 update
18th Mar 20203:14 pmRNSAdditional Listing
17th Mar 202010:25 amRNSDirector/PDMR Shareholding
12th Mar 202010:36 amRNSDirector/PDMR Shareholding
10th Mar 20202:02 pmRNSDirector/PDMR Shareholding
9th Mar 202010:57 amRNSDirector/PDMR Shareholding
6th Mar 20202:36 pmRNSDirector/PDMR Shareholding
6th Mar 20202:35 pmRNSDirector/PDMR Shareholding
5th Mar 20201:41 pmRNSDirector/PDMR Shareholding
4th Mar 20207:00 amRNS2019 Preliminary Results Announcement
2nd Mar 20203:46 pmRNSBlock listing Interim Review
2nd Mar 202011:22 amPRNTotal Voting Rights
4th Feb 20207:00 amRNSDirectorate Change
21st Jan 20208:46 amPRNDirector Declaration
20th Jan 202010:54 amPRNHolding(s) in Company
14th Jan 20207:00 amRNSTrading update
6th Jan 202010:09 amPRNHolding(s) in Company
2nd Jan 202011:12 amPRNTotal Voting Rights
2nd Dec 201912:15 pmPRNTotal Voting Rights
19th Nov 20197:00 amRNS2019 Capital Markets Day
1st Nov 20199:33 amPRNTotal Voting Rights
31st Oct 20197:00 amRNSQ3 Trading Update
4th Oct 20197:52 amPRNDirectorate Change
30th Sep 20197:00 amPRNAppointment of joint corporate broker
2nd Sep 201910:00 amPRNBlocklisting - Interim Review
15th Aug 201910:34 amPRNDirector/PDMR Shareholding
1st Aug 20193:42 pmPRNHolding(s) in Company
30th Jul 20197:00 amRNSHalf-year Report
25th Jul 201910:14 amPRNHolding(s) in Company
6th Jun 20195:42 pmPRNDirector/PDMR Shareholding
6th Jun 20195:39 pmPRNDirector/PDMR Shareholding
7th May 201910:33 amPRNDirector Declaration
7th May 20198:57 amPRNDirector Declaration
2nd May 20192:38 pmPRNHolding(s) in Company
30th Apr 20191:00 pmPRNResult of AGM
30th Apr 20197:00 amRNSAGM Trading Statement
18th Apr 20193:23 pmPRNHolding(s) in Company
17th Apr 20192:43 pmPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.